Drug intelligence / Profile preview

alveavax

Development stage: Phase 1
Lead developer: Alvea Holdings
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intradermal, Subcutaneous

Overview

Alveavax is a plasmid DNA-based vaccine developed by Alvea for the prevention of COVID-19, specifically targeting the SARS-CoV-2 Omicron and BA.2 variants. The vaccine works by introducing DNA encoding viral antigens into host cells, prompting them to produce these antigens and thereby stimulating an immune response against the virus. Alveavax is administered via intradermal or subcutaneous injection and has been evaluated in a Phase I clinical trial as a booster in individuals previously vaccinated with Ad26.COV2.S (Janssen) COVID-19 vaccine[1][3][7].

Other names: alveavax-v1.2alveavax-v-1.2alveavax-v 1.2

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on alveavax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alveavax.

Explore the full profile